Hainan Haiyao: Announcement on Signing Lease Agreements and Related Transactions
Hainan Haiyao: Legal Opinion on the 2024 First Extraordinary General Meeting of Shareholders of Hainan Haiyao Co., Ltd.
Hainan Haiyao: Hainan Haiyao: Articles of Association (revised in April 2024)
Hainan Haiyao: Announcement of Resolutions of the 2024 First Extraordinary General Meeting of Shareholders
Hainan Haiyao: Notice on Convening the First Extraordinary General Meeting of Shareholders in 2024
Hainan Haiyao: Announcement on the progress of the debt repayment agreement
Hainan Haiyao: Progress Notice on Signing Debt Repayment Agreements
Hainan Haiyao: Announcement on Wholly-owned Subsidiaries Obtaining High-tech Enterprise Certificates
Hainan Haiyao: Announcement on Signing a Debt Repayment Agreement
Hainan Haiyao: Announcement on the Wholly-owned Subsidiary Obtaining Supplemental Application Approval for Fengliao Gastroenterology Oral Liquid and Becoming a Drug Marketing License Holder
Hainan Haiyao: Announcement on Subsidiaries Receiving Government Subsidies
Hainan Haiyao: Announcement on amending the “Articles of Association”
Hainan Haiyao: Announcement on the Wholly-owned Subsidiary Obtaining Supplemental Application Approval for the Shuangshen Active Blood Channel Granule Drug and Becoming a Drug Marketing License Holder
Hainan Haiyao: Announcement on the progress of the lawsuit
Hainan Haiyao: Announcement on the Company\'s Filing of a Lawsuit
Hainan Haiyao: Legal Opinions of the Fourth Extraordinary General Meeting of Shareholders in 2023
Hainan Haiyao: Announcement of Resolutions of the Fourth Extraordinary General Meeting of Shareholders in 2023
Hainan Haiyao: Notice on Holding the Fourth Extraordinary General Meeting of Shareholders in 2023
Hainan Haiyao: Notice on the Company and the Former Actual Controller Received a Case Filing Notice from the China Securities Regulatory Commission
Hainan Haiyao: Announcement on receiving the summary report of the phase I clinical trial of a new drug, pinegabine tablets
No Data